Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cmi.2020.09.014 http://scihub22266oqcxt.onion/10.1016/j.cmi.2020.09.014 32971254!7506332!32971254     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Microbiol+Infect 2021 ; 27 (1): 105-111 Nephropedia Template TP {{tp|p=32971254|t=2021. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study |pdf=|usr=}}{{32971254}} gab.com Text Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study JO: Clin Microbiol Infect http://www.kidney.de/pget.php?&tw=1&pmid=32971254 #FOAvip OBJECTIVE: To assess the efficacy of corticosteroids in patients with coronavirus disease 2019 (COVID-19). METHODS: A multicentre observational study was performed from 22 February through 30 June 2020. We included consecutive adult patients with severe COVID-19, defined as respiratory rate >/=30 breath per minute, oxygen saturation </=93% on ambient air or arterial partial pressure of oxygen to fraction of inspired oxygen </=300 mm Hg. We excluded patients being treated with other immunomodulant drugs, receiving low-dose corticosteroids and receiving corticosteroids 72 hours after admission. The primary endpoint was 30-day mortality from hospital admission. The main exposure variable was corticosteroid therapy at a dose of >/=0.5 mg/kg of prednisone equivalents. It was introduced as binomial covariate in a logistic regression model for the primary endpoint and inverse probability of treatment weighting using the propensity score. RESULTS: Of 1717 patients with COVID-19 evaluated, 513 were included in the study, and of these, 170 (33%) were treated with corticosteroids. During hospitalization, 166 patients (34%) met the criteria of the primary outcome (60/170, 35% in the corticosteroid group and 106/343, 31% in the noncorticosteroid group). At multivariable analysis corticosteroid treatment was not associated with lower 30-day mortality rate (adjusted odds ratio, 0.59; 95% confidence interval (CI), 0.20-1.74; p 0.33). After inverse probability of treatment weighting, corticosteroids were not associated with lower 30-day mortality (average treatment effect, 0.05; 95% CI, -0.02 to 0.09; p 0.12). However, subgroup analysis revealed that in patients with PO2/FiO2 < 200 mm Hg at admission (135 patients, 52 (38%) treated with corticosteroids), corticosteroid treatment was associated with a lower risk of 30-day mortality (23/52, 44% vs. 45/83, 54%; adjusted odds ratio, 0.20; 95% CI, 0.04-0.90; p 0.036). CONCLUSIONS: The effect of corticosteroid treatment on mortality might be limited to critically ill COVID-19 patients. Twit Text FOAVip Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study ????Clin Microbiol Infect http://www.kidney.de/pget.php?&tw=1&pmid=32971254 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32971254 #FOAvip English Wikipedia <ref>{{Cite pmid|32971254}}</ref> Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study #MMPMID32971254 Bartoletti M; Marconi L; Scudeller L; Pancaldi L; Tedeschi S; Giannella M; Rinaldi M; Bussini L; Valentini I; Ferravante AF; Potalivo A; Marchionni E; Fornaro G; Pascale R; Pasquini Z; Puoti M; Merli M; Barchiesi F; Volpato F; Rubin A; Saracino A; Tonetti T; Gaibani P; Ranieri VM; Viale P; Cristini F Clin Microbiol Infect 2021[Jan]; 27 (1): 105-111 PMID32971254show ga OBJECTIVE: To assess the efficacy of corticosteroids in patients with coronavirus disease 2019 (COVID-19). METHODS: A multicentre observational study was performed from 22 February through 30 June 2020. We included consecutive adult patients with severe COVID-19, defined as respiratory rate >/=30 breath per minute, oxygen saturation /=0.5 mg/kg of prednisone equivalents. It was introduced as binomial covariate in a logistic regression model for the primary endpoint and inverse probability of treatment weighting using the propensity score. RESULTS: Of 1717 patients with COVID-19 evaluated, 513 were included in the study, and of these, 170 (33%) were treated with corticosteroids. During hospitalization, 166 patients (34%) met the criteria of the primary outcome (60/170, 35% in the corticosteroid group and 106/343, 31% in the noncorticosteroid group). At multivariable analysis corticosteroid treatment was not associated with lower 30-day mortality rate (adjusted odds ratio, 0.59; 95% confidence interval (CI), 0.20-1.74; p 0.33). After inverse probability of treatment weighting, corticosteroids were not associated with lower 30-day mortality (average treatment effect, 0.05; 95% CI, -0.02 to 0.09; p 0.12). However, subgroup analysis revealed that in patients with PO2/FiO2 < 200 mm Hg at admission (135 patients, 52 (38%) treated with corticosteroids), corticosteroid treatment was associated with a lower risk of 30-day mortality (23/52, 44% vs. 45/83, 54%; adjusted odds ratio, 0.20; 95% CI, 0.04-0.90; p 0.036). CONCLUSIONS: The effect of corticosteroid treatment on mortality might be limited to critically ill COVID-19 patients. |*COVID-19 Drug Treatment[MESH] |Adrenal Cortex Hormones/*therapeutic use[MESH] |Adult[MESH] |Aged[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19/*mortality/pathology[MESH] |Critical Illness[MESH] |Female[MESH] |Heparin, Low-Molecular-Weight/therapeutic use[MESH] |Hospital Mortality[MESH] |Hospitals[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Italy[MESH] |Length of Stay/statistics & numerical data[MESH] |Male[MESH] |Middle Aged[MESH] |Odds Ratio[MESH] |Respiratory Distress Syndrome/*drug therapy/*mortality/pathology[MESH] |Retrospective Studies[MESH] |SARS-CoV-2/drug effects/*pathogenicity[MESH] |Severity of Illness Index[MESH] |Survival Analysis[MESH]Efficacy of corticosteroid treatment for hospitalized patients with se(epmc).pdf DeepDyve Pubget Overpricing